title: Aprotinin reduces the need for blood products during liver transplantation.
abstract: BACKGROUND
  Bleeding complications and blood product consumption have been a major concern during liver transplantation. Prevention of plasminogen activation and fibrinolysis by aprotinin administration has been shown to reduce perioperative bleeding during operations associated with high blood-product consumption.
  
  
  METHODS
  Use of blood-products (packed red cells, frozen plasma, platelets, and cryoprecipitate) was analyzed both during the three stages of orthotopic liver transplantation and during total hospitalization of the 26 patients transplanted without aprotinin and the subsequent 40 patients with aprotinin. A similar analysis was performed for 15 patients immediately before and after the introduction of aprotinin to eliminate the "learning curve" effect for liver transplantation. The effect of epsilon-amino-caproic acid was analyzed as 13 patients received neither epsilon-aminocaproic acid nor aprotinin and 13 patients received epsilon-aminocaproic acid but not aprotinin.
  
  
  RESULTS
  There was a significant reduction in total hospital use of cryoprecipitate, frozen plasma, platelets, and red cells in the aprotinin-treated patients. This reduction was seen during the anhepatic and reperfusion stages of liver transplantation. There was no difference in blood product consumption between the groups who were or were not treated with epsilon-aminocaproic acid.
  
  
  CONCLUSIONS
  Aprotinin significantly reduces the need for red cell, frozen plasma, platelet, and cryoprecipitate transfusion use during orthotopic liver transplantation, and appears to be more efficacious than epsilon-aminocaproic acid.
authors.affiliation: Section of Hepatobiliary and Pancreatic Surgery, University of British Columbia, Vancouver, Canada.
authors.forename: C H
authors.initials: CH
authors.lastname: Scudamore
authors.forename: T E
authors.initials: TE
authors.lastname: Randall
authors.forename: P J
authors.initials: PJ
authors.lastname: Jewesson
authors.forename: C R
authors.initials: CR
authors.lastname: Shackleton
authors.forename: A J
authors.initials: AJ
authors.lastname: Salvian
authors.forename: M
authors.initials: M
authors.lastname: Fagan
authors.forename: L
authors.initials: L
authors.lastname: Frighetto
authors.forename: G H
authors.initials: GH
authors.lastname: Growe
authors.forename: I
authors.initials: I
authors.lastname: Scarth
authors.forename: S R
authors.initials: SR
authors.lastname: Erb
mesh_terms: D000293:Adolescent; D000328:Adult; D000418:Albumins / Q000008:administration & dosage; D000614:Aminocaproates / Q000008:administration & dosage; D007611:Aprotinin / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control* / Q000706:statistics & numerical data; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D015925:Cryopreservation; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D006801:Humans; D016031:Liver Transplantation / Q000379:methods*; D008875:Middle Aged; D010951:Plasma Exchange / Q000706:statistics & numerical data; D017713:Platelet Transfusion / Q000706:statistics & numerical data; D012086:Reoperation; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D000614:Aminocaproates; D007611:Aprotinin